Lucia Del Mastro
YOU?
Author Swipe
View article: Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients Open
PROFFIT validation analyses make the instrument suitable to measure FT in cancer patients within public health systems. In addition, it may represent a valuable tool to plan specific local health policies being sensible to macro-regional v…
View article: Fertility and ovarian function preservation in young women with breast cancer: A joint analysis of the Joven & Fuerte and PREFER prospective studies
Fertility and ovarian function preservation in young women with breast cancer: A joint analysis of the Joven & Fuerte and PREFER prospective studies Open
FP and ovarian protection uptake were markedly higher in Italy than Mexico, possibly reflecting divergent social and healthcare contexts, though cryopreservation remained underutilized in both countries. Improved access to oncofertility se…
View article: Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer Open
View article: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial Open
View article: Weight Changes during Early Breast Cancer Treatment and Their Association with Survival: An Exploratory Functional Data Analysis of GIM-2 Trial
Weight Changes during Early Breast Cancer Treatment and Their Association with Survival: An Exploratory Functional Data Analysis of GIM-2 Trial Open
Introduction Limited evidence is available on the impact of early breast cancer (EBC) treatments on body weight. Notably, robust data quantifying the magnitude and timing of weight changes during treatment are lacking, and existing finding…
View article: Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review Open
Background: Hormone-receptor-positive (HR+)/HER2-negative (HER2−) breast cancer (BC) is characterized by low immunogenicity and an immunosuppressive microenvironment. These features likely contribute to the inconsistent clinical activity o…
View article: Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses Open
Our results indicate that neoadjuvant/perioperative immunotherapy should be considered the standard. This should be preferred over upfront surgery, also in stage II, PD-L1-negative and squamous histology.
View article: The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial Open
Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with adv…
View article: Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis Open
Background Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are the standard-of-care for hormone receptor-positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC). Palbociclib, the first approved …
View article: Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy Open
View article: A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients Open
View article: Breastfeeding after breast cancer in young <i>BRCA</i> carriers
Breastfeeding after breast cancer in young <i>BRCA</i> carriers Open
Background We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods This was an international, multicenter, hospital-based, retrospective cohort study …
View article: Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER) Open
Background Trastuzumab combined with chemotherapy is a standard treatment for HER2-positive advanced breast cancer in later lines. Lapatinib and trastuzumab have also demonstrated efficacy. This study assessed the efficacy, toxicity, and q…
View article: PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)]
PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)] Open
View article: The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report Open
View article: Letter response re: factors associated with first-to-second line attrition among patients with metastatic breast cancer in the real-world
Letter response re: factors associated with first-to-second line attrition among patients with metastatic breast cancer in the real-world Open
View article: 209P Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trial
209P Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trial Open
View article: Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance
Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance Open
Endocrine therapy (ET) is a cornerstone in the management of patients with hormone receptor-positive early breast cancer, which accounts for over 70% of cases worldwide. The efficacy of adjuvant ET for 5 years in reducing the risk of recur…
View article: Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study Open
View article: Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies Open
View article: Prognostic implications of risk definitions from the monarchE and NATALEE trials
Prognostic implications of risk definitions from the monarchE and NATALEE trials Open
Background The monarchE and NATALEE trials employed different high-risk inclusion criteria. The main objective is to assess prognostic differences based on their inclusion criteria. Methods Patients with hormone receptor-positive/HER2-nega…
View article: Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world Open
View article: Insights on the Association of Anthropometric and Metabolic Variables with Tumor Features and Genomic Risk in Luminal Early Breast Cancer: Results of a Multicentric Prospective Study
Insights on the Association of Anthropometric and Metabolic Variables with Tumor Features and Genomic Risk in Luminal Early Breast Cancer: Results of a Multicentric Prospective Study Open
View article: Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report
Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report Open
Breast cancer (BC) is the most common malignancy among women. Among 5%–10% of diagnoses are correlated with hereditary cancer syndromes, while the remaining cases are sporadic and linked to multiple factors. When a pathogenetic variant in …
View article: Analysis of Artificial Intelligence Decision-Making in Hormone Receptor-Positive / Human Epidermal Growth Factor 2-Negative Early Breast Cancer within Routine Clinical Practice and Clinical Trial
Analysis of Artificial Intelligence Decision-Making in Hormone Receptor-Positive / Human Epidermal Growth Factor 2-Negative Early Breast Cancer within Routine Clinical Practice and Clinical Trial Open
View article: Comparison of Suboptimal Versus Adequate Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer Treated with Adjuvant Endocrine Therapy: An Exploratory Analysis of Two Prospective Studies
Comparison of Suboptimal Versus Adequate Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer Treated with Adjuvant Endocrine Therapy: An Exploratory Analysis of Two Prospective Studies Open
View article: Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients Open
View article: Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer Open
View article: Identifizierung von Patientinnen mit HR+, HER2– Brustkrebs im Frühstadium mit hohem Rezidivrisiko
Identifizierung von Patientinnen mit HR+, HER2– Brustkrebs im Frühstadium mit hohem Rezidivrisiko Open
Die Inzidenz von Brustkrebs ist in den letzten 2 Jahrzehnten gestiegen; gleichzeitig hat sich das Überleben durch eine frühere Erkennung und bessere Therapiemöglichkeiten verbessert. Trotz dieser Verbesserungen treten lokoregionäre Rezidiv…
View article: Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions Open